The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

“…Psoriasis lesions, nonlesional skin, and normal skin were obtained from patients and normal volunteers under an approved protocol (The Rockefeller University). Experiments were conducted on samples obtained from a previously published placebo-controlled clinical trial with efalizumab (n ϭ 65) (Genentech and Xoma) (5). Patients treated with efalizumab showed greater clinical improvement and reduction of epidermal hyperplasia in skin lesions compared to placebo treatment.…”

“…Evidence for this view includes (i) a marked increase in the number of T cells in diseased skin, (ii) the differentiation characteristics of these T cells, including a skin-homing memory phenotype, a T helper 1͞Tc1 predominance, and oligoclonality, and (iii) the disease improvements brought about by a variety of T cell-targeted immunosuppressive agents (4)(5)(6). T cell functions are often controlled by dendritic cells (DCs), and interestingly, psoriasis is characterized by the production of IL-23 by CD11c ϩ DCs in lesional skin (7).…”

Neue monoklonale Antikörper und ihr Einsatz in der Dermatologie

“…Etanercept verwendet (Übersicht in [1,2] [19,20]. Da diese Studien auch der Dosisfindung dienten, zeigten sich Reduktionen des PASI-Scores, die von 10 % (0,1 mg/kg KG) bis zu 47 % (1 mg/kg KG) reichten.…”

New Therapeutic Challenges in Autoimmune Diseases

“…It binds to ICAM-1 on antigen-presenting cells and functions as an adhesion molecule. Anti-LFA1 Ab treatment elicited an improvement in psoriasis (Papp et al, 2001;Tutrone et al, 2001). …”